hyperactivity
Intrahippocampal infusion studies with the AMPA-specific inhibitor GYKI 52466 [4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzenamine hydrochloride], a GluR1-specific TAT-S845 peptide, showed that GluR1/2 was essential for the development of manic/hedonic-like behaviors such as amphetamine-induced hyperactivity.
Intrahippocampal infusion studies with the AMPA-specific inhibitor GYKI 52466 [4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzenamine hydrochloride], a <span class="gene" id="18171924-6-167-172">GluR1</span>-specific TAT-S845 peptide, showed that <span class="gene" id="18171924-6-212-217">GluR1</span>/2 was essential for the development of manic/hedonic-like behaviors such as amphetamine-induced <span class="disease" id="18171924-6-314-327">hyperactivity</span>.